The 2.3 percent excise tax on the medical devices sector would hamper innovation, force layoffs and cripple loss-making start-ups.
David Lucchino is co-founder of Semprus BioSciences. He also co-founded LaunchCyte, an investment firm that specializes in developing biomedical intellectual property. He is a trustee of Mt. Auburn Hospital and earned an MBA from MIT.